Department of Clinical Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
Ontario Patient-Reported Outcomes of Symptoms and Toxicity, Princess Margaret Cancer Center and Ontario Cancer Institute, University Health Network, University of Toronto, Toronto, Ontario, Canada.
J Am Acad Dermatol. 2014 Oct;71(4):754-9. doi: 10.1016/j.jaad.2014.06.011. Epub 2014 Jul 29.
Dermatologic toxicities from targeted agents such as panitumumab can interfere with cancer treatment.
We sought to evaluate the rash assessment and management in a consecutive patient cohort who received panitumumab for colorectal cancer treatment.
This was a retrospective chart review.
Skin toxicity, consisting of papulopustular rash, was experienced by 32 of 34 patients. The majority (85%) developed the rash by the end of the second infusion cycle. Patients presented with a mild (41%), moderate (38%), and severe (21%) rash, and progressed to an extensive rash without appropriate treatment. A grading system was used for 65% of patients to document severity.
Small sample size limited power in analysis. Rash severity had to be inferred based on rash description and management in 11 of the patients.
Dermatologic toxicities related to panitumumab are common; however, the way they are reported and managed varies among physicians. To prevent progression, toxicities must be assessed and treated early and aggressively, according to severity grading. Dermatologists could aid oncologists in choosing the best management strategies.
靶向药物（如帕尼单抗）引起的皮肤毒性会干扰癌症治疗。
我们旨在评估连续接受帕尼单抗治疗结直肠癌患者的皮疹评估和管理情况。
这是一项回顾性图表审查。
34 名患者中有 32 名出现皮肤毒性，主要表现为脓疱性皮疹。大多数（85%）在第二输注周期结束时出现皮疹。患者的皮疹表现为轻度（41%）、中度（38%）和重度（21%），且未经适当治疗进展为广泛皮疹。65%的患者使用了分级系统来记录严重程度。
样本量小限制了分析的效能。由于 11 名患者的皮疹描述和管理不完整，因此必须根据这些信息推断皮疹的严重程度。
与帕尼单抗相关的皮肤毒性很常见；然而，医生报告和管理的方式存在差异。为了防止病情进展，必须根据严重程度分级，尽早积极评估和治疗毒性。皮肤科医生可以帮助肿瘤学家选择最佳的管理策略。
